Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA-DUET azole-echinocandin combination therapy trial for invasive aspergillosis
NL-OMON52868Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of voriconazole, isavuconazole, posaconazole and anidulafungin in invasive aspergillosis (IA) and aspergillosis (2 arms), sponsored by Erasmus MC. Primary endpoint: Overall survival at 6 weeks in the MITT population. Started Jul 2021; status: recruiting.
02
Drugs
voriconazoleisavuconazoleposaconazoleanidulafungin
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on NL-OMON52868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52868.